FDA Fast Track Leverage the FDA Fast Track designation for ADP101 to engage potential partners, suppliers, and contract manufacturers who can accelerate development, manufacturing scalability, and regulatory readiness for multi-allergen oral immunotherapy.

Phase 1/2 Momentum capitalize on the Harmony study data and ongoing Phase 1/2 progress to attract licensing discussions, co-development opportunities, and strategic alliances with larger biotech players seeking late-stage readiness in food allergy therapeutics.

Significant Funding Backing With substantial funding already secured, pursue partnerships for manufacturing scale, global clinical trial expansion, and market access planning, while offering favorable financial terms to collaborators seeking rapid value infusion.

Specialized Niche Focus Target allergen-focused healthcare networks, specialty pharmacies, and immunology clinics that require new oral immunotherapy options, building pilot programs or compassionate-use pathways for ADP101 in university hospitals and dedicated allergy centers.

Early Market Signals Monitor regulatory milestones and safety data presentations to time outreach to payers, patient advocacy groups, and distribution partners, positioning ADP101 as a leading multi-allergen solution with potential for Fast Track-driven pricing and access strategies.